Evidence map›Paper›PMID 39332922›Full record

ArticleClinical lung cancer2024

Smoking and the Risk of Second Primary Lung Cancer Among Breast Cancer Survivors from the Population-Based UK Biobank Study.

Anna Graber-Naidich, Eunji Choi, Julie T Wu, Timothy J Ellis-Caleo, Joel Neal, Heather A Wakelee, Allison W Kurian, Summer S Han

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical lung cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Anna Graber-NaidichQuantitative Sciences Unit, Stanford University, Stanford, CA.
Eunji ChoiQuantitative Sciences Unit, Stanford University, Stanford, CA; Department of Population Health Sciences, Weill Cornell Medicine, New York, NY.
Julie T WuQuantitative Sciences Unit, Stanford University, Stanford, CA.
Timothy J Ellis-CaleoDepartment of Hematology, Stanford University School of Medicine, Stanford, CA.
Joel NealDepartment of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA.
Heather A WakeleeDepartment of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA.
Allison W KurianDepartment of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA; Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA.
Summer S HanQuantitative Sciences Unit, Stanford University, Stanford, CA; Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA. Electronic address: summer.han@stanford.edu.

Funding

Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI Vittorio Sebastiano · 2007 to 2026
$71.4M
Evaluation of genetic, clinical, and environmental risk factors to establish effective screening strategies for second primary lung cancerR37CA226081 · NCI · STANFORD UNIVERSITY · PI HAN, SUMMER S · 2018 to 2024
$4.3M
Integrating Multiple Electronic Health Records Systems to Improve Lung Cancer OutcomesR01CA282793 · NCI · STANFORD UNIVERSITY · PI Summer S Han · 2023 to 2026
$2.6M
NCI NIH HHS P30 CA124435NCI NIH HHS R01 CA282793NCI NIH HHS R37 CA226081
6 · The paper itself

Abstract

objectiveLong-term breast cancer (BC) survivors are known to develop second malignancies, with second primary lung cancer (SPLC) one common type. Smoking was identified as a main risk factor for SPLC among BC survivors. These findings were limited to the U.S. and focused on smoking status, not incorporating cumulative smoking exposures (eg, pack-years). We examine SPLC incidence and evaluate the associations between SPLC risk and cumulative cigarette smoking exposures and other potential factors among BC survivors in a prospective European cohort.

methodsOf 502,505 participants enrolled in the UK Biobank in 2006 to 2010, we identified 8429 patients diagnosed with BC between 2006 and 2016 and followed for second malignancies through 2016. Smoking information was collected at enrollment, and treatment data were collected using electronic health records. Multivariable cause-specific Cox regression (CSC) evaluated the association between each factor and SPLC risk.

resultsOf 8429 BC patients, 40 (0.47%) developed SPLC over 45,376 person-years. The 10-year cumulative SPLC incidence was 0.48% (95% CI = 0.33%-0.62%). The CSC analysis confirmed the association between SPLC and ever-smoking status (adjusted hazard-ratio (aHR) = 3.46 (P < .001). The analysis showed a 24% increment in SPLC risk per 10 smoking pack-years among BC survivors (aHR = 1.24 per-10 pack-years, P = .01). The associations between SPLC and other variables remained statistically insignificant. We applied the USPSTF lung cancer screening eligibility criteria and found that 80% of the 40 BC survivors who developed SPLC would have been ineligible for lung cancer screening.

conclusionIn a large, European cohort, cumulative smoking exposure is significantly associated with SPLC risk among BC survivors.

Indexed as

Biological Specimen BanksBreast NeoplasmsCancer SurvivorsLung NeoplasmsNeoplasms, Second PrimarySmokingAdultAgedCohort StudiesFemaleFollow-Up StudiesHumansIncidenceMiddle AgedProspective StudiesRisk FactorsBreast cancerBreast CancerSecond Primary Lung CancerSmoking

Identifiers

PMID39332922
PMCPMC12316059

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.